Atrium Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Avidity Biosciences, Inc. Avidity Biosciences, Inc. (NASDAQ: RNA) develops targeted RNA therapeutics using its proprietary Antibody Oligonucleotide Conjugates (AOC) platform, which combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies to address genetic drivers of previously untreatable diseases. The company focuses on rare muscle diseases, with three clinical-stage programs: delpacibart etedesiran (del-desiran, AOC 1001) in Phase 3 HARBOR trial and MARINA-OLE for myotonic dystrophy type 1 (DM1); delpacibart braxlosiran (del-brax, AOC 1020) in Phase 1/2 FORTITUDE trial for facioscapulohumeral muscular dystrophy (FSHD), with plans to accelerate registrational cohorts; and delpacibart zotadirsen (del-zota, AOC 1044) in Phase 2 EXPLORE44-OLE for Duchenne muscular dystrophy (DMD) amenable to exon 44 skipping, as the first of multiple DMD-targeted AOCs. It expands its pipeline into precision cardiology and immunology through internal discovery and partnerships, targeting additional tissues like cardiac and immune cells; operations center on the biotechnology sector serving patients with rare genetic neuromuscular disorders. Founded in 2012 and headquartered in San Diego, California, at 10578 Science Center Drive, Suite 125, the company licenses foundational technology from The Scripps Research Institute and maintains a diverse team emphasizing research, development, and commercial execution across the United States. In a major strategic development announced October 26, 2025, Novartis agrees to acquire Avidity Biosciences for $12 billion through a merger, strengthening Novartis's neuroscience franchise with Avidity's late-stage AOC programs for neuromuscular diseases while spinning out early-stage precision cardiology assets to a new subsidiary prior to closing, following board approvals by both companies.
Company News
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Atrium Therapeutics (NASDAQ: RNA) lines up $50 million private placement
Atrium Therapeutics Announces $50 Million Private Placement
Avidity Biosciences (NASDAQ:RNA) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Avidity Biosciences (NASDAQ:RNA) Stock Price Crosses Below 200-Day Moving Average – Here’s Why
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Reports First Quarter 2026 Financial Results
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low – Here’s Why
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies